Search Results Label

Seqirus has been on the front line of pandemic preparedness for more than a century. Learn more about our rapid vaccine production capabilities.

https://www.seqirus.com/expertise/influenza/pandemic-response-solutions

Seqirus will develop and evaluate two influenza A(H2Nx) virus vaccine candidates in support of U.S. government pandemic preparedness objectives

https://www.seqirus.com/news/seqirus-awarded-us-government-contract-for-two-influenza-vaccines

Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.

https://www.seqirus.com/expertise

Seqirus is one of the largest influenza vaccine companies in the world, with state-of-the-art manufacturing facilities on three continents. Learn more.

https://www.seqirus.com/manufacturing/global-manufacturing-network

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.com/news

Seqirus appoints Roberta Duncan as new program lead to drive sa-mRNA technology advancement. Accelerates development of sa-mRNA vaccine candidates for seasonal and pandemic influenza.

https://www.seqirus.com/news/seqirus-invests-in-self-amplifying-messenger-rna-technology

First doses of Seqirus’s enhanced influenza vaccine, destined for the U.K., come off a new high-speed fill-and-finish line in Liverpool.

https://www.seqirus.com/news/high-speed-fill-and-finish-in-liverpool

A panel of leading international experts discuss the challenges of the oncoming influenza season at this year’s EU Flu Day

https://www.seqirus.com/news/eu-flu-day-2021

Seqirus announced today that the accelerated development of cell-based manufacturing technology at its manufacturing facility in Holly Springs, North Carolina, has delivered a four-fold increase in seasonal influenza vaccine output in just two years, strengthening the United States’ capacity to respond to pandemic threats.

https://www.seqirus.com/news/seqirus-announces-major-advances-in-pandemic-preparedness

NEJM study indicates that the seasonal influenza vaccine was effective and produced a sufficient immune response against influenza in children and adolescents ≥2 to <18 years of age

https://www.seqirus.com/news/nejm-study-cell-based-quadrivalent-influenza-vaccine-efficacy-in-children